Flu & COVID-19 Home Test Now Available

Lucira Health, Inc. announced today both the nationwide launch of its breakthrough Lucira COVID-19 & Flu Home Test in the United States and the combination test's inclusion in the Australian Register of Therapeutic Goods for use by healthcare professionals in a point-of-care setting.

The COVID-19 & Flu Home Test is the first and only combination COVID-19 & Flu test to be granted emergency use authorization by the U.S. Food and Drug Administration for over-the-counter (OTC) use at home and other non-laboratory sites.

The all-in-one combination test delivers results from one shallow nasal swab in 30 minutes or less.

This OTC test is a molecular nucleic acid amplification test, not an antigen test.

The Lucira COVID-19 & Flu Home Test is a molecular test demonstrating similar performance for COVID-19 and Influenza compared to highly sensitive lab-based PCR tests in clinical trials.

"Both of these accomplishments represent important milestones for Lucira and underscore the viability of the Lucira technology platform in both at-home and point-of-care settings around the globe," said Erik Engelson, President and CEO of Lucira Health, in a press release on March 28, 2023.

"U.S. consumers will, for the first time ever, be able to diagnose if they have COVID-19 or Flu A or B while at home."

"With one-touch access to telehealth via our Lucira Connect web platform, they can now get onto the path to treatment and recovery within hours of receiving a test result from the comfort of home."

This test can be purchased in the U.S. for $34.99 at www.lucirahealth.com/flu.